{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Foncologypodcast.simplecast.com%2Fepisodes%2Fgep-nets-podcast-amQntHfi","width":444,"version":"1.0","type":"rich","title":"Gastroenteropancreatic Neuroendocrine Tumors: Diagnosis, Findings, and Recommendations","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/90abc814-7d95-4f5e-bc85-33a51d717e47/9242-onc-2024-gep-net-tm-podcast.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/f0aad2b7-0532-4607-bff9-805661118521\" height=\"200\" width=\"100%\" title=\"Gastroenteropancreatic Neuroendocrine Tumors: Diagnosis, Findings, and Recommendations\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Listen as Thor R. Halfdanarson, MD, and Jonathan Strosberg, MD, discuss the diagnosis and typical presenting symptoms of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) as well as findings from recent phase III studies including NETTER-2 and CABINET. Notable clinical pearls regarding GEP-NET therapies and current guidelines for GEP-NET care and monitoring are also highlighted."}